FDA Breakthrough Device Designation: Criteria, Benefits, and Medicare Realities

2026-09-10 · Caduvo Team

FDA Breakthrough Device Designation accelerates regulatory review, but it does not guarantee Medicare coverage. Here is how the program works and what it means for your reimbursement roadmap.

Founders of novel medtech companies often treat an FDA Breakthrough Device designation as an all-in-one commercial passport. Pitch decks frequently present the designation as an expedited track through regulatory review that immediately clears the path to hospital adoption and commercial payment. That assumption burns capital.

While the program offers procedural advantages inside the FDA, it does not guarantee third-party reimbursement. FDA market authorization and Medicare coverage operate under separate legal authorities, distinct evidentiary requirements, and disconnected agency timelines. Securing designation alters your regulatory interactions with review teams, but your reimbursement roadmap remains an independent operational challenge unless you design your clinical data to satisfy both regulatory and coverage standards.

The Statutory Criteria: Does Your Technology Qualify?

The Breakthrough Devices Program is a voluntary program authorized under Section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360e-3), created by Section 3051 of the 21st Century Cures Act and amended by the FDA Reauthorization Act of 2017 and Section 3001 of the SUPPORT for Patients and Communities Act. The program superseded the Expedited Access Pathway (EAP) and Priority Review. To qualify, a product must be a medical device or device-led combination product subject to a Premarket Approval application (PMA), a premarket notification [510(k)], or a De Novo classification request. If you are assessing which premarket route applies to your system, examine our guide comparing 510(k) vs PMA vs De Novo pathways.

According to the FDA Breakthrough Devices Program guidance, a device must satisfy two statutory criteria outlined in Section 515B(b) of the FD&C Act:

  1. Criterion 1 (Disease Severity): The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions. As outlined in FDA panel presentations on the program, life-threatening conditions carry a high likelihood of death unless the course of disease is interrupted (such as primary and metastatic bone tumors). Irreversibly debilitating conditions impact survival, everyday functioning, or carry a high likelihood of progressing to a more serious disease if left untreated (such as severe osteoarthritis or degenerative spinal disorders). The sponsor must demonstrate a reasonable expectation of technical success (the device functions as intended) and clinical success (the device more effectively treats or diagnoses the condition) supported by literature or preliminary data from bench, animal, or clinical testing.
  2. Criterion 2 (Technology Advantage): The device must satisfy at least one of four statutory prongs:

Policy expansions have broadened these criteria over time. On September 14, 2023, the FDA issued updated final guidance, officially published in the Federal Register on September 15, 2023 (88 FR 63582). This update clarified that CDRH considers technologies that address health and healthcare disparities by improving diagnosis or treatment in populations experiencing disparities. The agency also confirmed that the program applies to certain non-addictive medical products intended to treat pain or addiction.

Demand for the program has grown steadily. According to an FDA Center for Devices and Radiological Health update, CDRH had granted breakthrough device designation to 831 devices and granted marketing authorization to 77 designated devices through June 30, 2023. These numbers highlight an operational reality: obtaining designation is common, but reaching marketing authorization remains demanding.

Practical Benefits During Premarket Review

Receiving breakthrough device designation does not relax statutory safety and effectiveness benchmarks. A PMA still requires valid scientific evidence demonstrating reasonable assurance of safety and effectiveness, while a 510(k) submission still requires demonstrating substantial equivalence. The program alters the speed, structure, and communication channels available throughout that evaluation.

Under FDA program principles, manufacturers of designated devices receive several operational review advantages:

Once granted, the designation stays with the device for subsequent submissions leading to marketing authorization. However, these review mechanisms address only premarket clearance or approval. They do not resolve how payers evaluate the device once it enters the commercial market.

The Reimbursement Picture: TCET, Inpatient Payment, and Coverage Realities

The most damaging mistake an early-stage team can make is assuming that an fda breakthrough device designation ensures insurance coverage. The FDA evaluates safety and effectiveness. Medicare and private commercial payers evaluate whether a device is reasonable, necessary, and clinically valuable for their enrolled populations. If you need a comprehensive overview of how these commercial components function, read our primer on how medical device reimbursement works.

The TCET Pathway (CMS-3421-FN)

On August 7, 2024, CMS published its final procedural notice establishing the Transitional Coverage for Emerging Technologies pathway (CMS-3421-FN). The TCET pathway creates an explicit Medicare coverage review process for certain FDA-designated Breakthrough Devices.

TCET coordinates coverage through existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) frameworks. CMS established clear parameters for the initiative:

Devices not admitted to the five annual TCET slots must secure reimbursement through standard avenues: local contractor policies via Local Coverage Determinations (LCDs), case-by-case claim adjudication, or traditional multi-year national coverage requests. Understanding the differences between local and national policies is essential; see our guide on NCDs vs LCDs in Medicare coverage for details on regional coverage variations.

Inpatient Payment and Inpatient Add-On Programs

For devices used in hospital inpatient procedures, coverage alone does not resolve facility payment. Inpatient admissions are paid through fixed Medicare Severity Diagnosis-Related Group (MS-DRG) prospective payment rates. When a novel technology adds significant device costs to an inpatient stay, hospital purchasing teams evaluate whether Medicare provides supplemental payment beyond the base DRG rate.

Manufacturers often evaluate inpatient add-on mechanisms, such as the new technology add on payment (NTAP) program, to help offset high initial technology acquisition costs for facilities. However, holding an FDA breakthrough device designation does not create immediate payment. Hospital adoption still depends on whether the device maps to viable clinical billing pathways, fits hospital operating margins, and secures payment approval within existing prospective payment structures.

The Coding Prerequisite

Coverage determinations and inpatient payment programs cannot function without valid medical billing codes. A device cannot be billed to Medicare or private insurers without designated coding. Outpatient procedures, physician services, and durable medical equipment depend on Current Procedural Terminology (CPT) codes managed by the American Medical Association or Healthcare Common Procedure Coding System (HCPCS) Level II codes administered by CMS. For a detailed breakdown of how these coding systems interact, consult our analysis of HCPCS vs CPT codes.

A breakthrough designation does not issue a CPT or HCPCS code. The coding application cycle runs on strict, separate administrative schedules. If a device receives marketing authorization without compatible coding in place, hospital billing departments cannot generate claims, leaving adoption stalled despite prioritized FDA clearance.

Platforms like Caduvo help regulatory and market-access teams map novel technologies to appropriate CPT and HCPCS codes, evaluate local coverage rules, and design clinical evidence strategies that satisfy both FDA and commercial payer expectations simultaneously.

Actionable Takeaways

To capitalize on the program without falling into commercial traps, follow these operational rules:

  1. Build Criterion 1 Evidence Early: Support your designation request with objective bench, animal, or preliminary clinical data proving a reasonable expectation of both technical and clinical success in treating life-threatening or irreversibly debilitating conditions.
  2. Engage CDRH Through Early Sprints: Use program mechanisms to discuss flexible clinical study designs directly with FDA review staff and identify opportunities to balance premarket data collection with postmarket studies.
  3. Do Not Count on TCET as Your Sole Coverage Plan: Because CMS anticipates accepting up to five devices per year into TCET, treat regional MAC coverage and commercial payer policies as your primary market access path rather than banking on rapid national coverage.
  4. Align Clinical Endpoints with Payer Priorities: The FDA assesses safety and effectiveness, while payers examine clinical value and improved health outcomes in the Medicare population. Incorporate endpoints that demonstrate measurable functional improvements or reductions in adverse events to support subsequent coverage decisions.
  5. Begin Coding Preparation Parallel to Clinical Trials: Identify whether your technology maps to existing CPT or HCPCS codes or requires new code applications. Securing coding takes months of administrative lead time and must be executed in parallel with your regulatory review.

Sources

  1. Breakthrough Devices Program | FDA
  2. CDRH Issues Updated Final Guidance on Breakthrough Devices Program | FDA
  3. Breakthrough Devices Program
  4. Final Notice — Transitional Coverage for Emerging Technologies (CMS-3421-FN) | CMS
  5. 63582

General information, not regulatory, legal or reimbursement advice. Company and product names belong to their owners; a mention does not imply affiliation or endorsement. Report an error. Data and corrections policy.

Related reading